Ultragenyx reports positive long-term data from Phase 1/2 gene therapy studies in GSDIa and OTC deficiency. May 14, 2021 9:03 AM ETUltragenyx ...
https://www.google.com/url?rct=j&sa=t&url=https://seekingalpha.com/news/3696612-ultragenyx-reports-positive-long-term-data-from-phase-12-gene-therapy-studies-in-gsdia-and-otc-deficiency&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNH3s4qlMkZexzmQVVAyEPaUabdRFQ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.